HALF-LIFE FACTOR CONCENTRATES
-
The CHS urges provinces to accept CBS recommendation to introduce Altuviiio
Montréal, December 12, 2025 – In a letter dated December 10, the Canadian Hemophilia Society (CHS) urged the Provincial/Territorial Blood Liaison Committee (P/TBLC) to accept...
-
Update on novel therapies for hemophilia A and B
MONTRÉAL, September 19, 2025 – No announcements have been made over the summer on progress in gaining access to two novel hemophilia therapies. Altuviiio for...
-
WFH mobilizes global community to achieve milestone revisions to WHO EML
While this does not affect Canada directly, it is a major step forward for the international community and acknowledges what Canada is already doing in...
-
Reimbursement of Altuviiio recommended, but…
MONTRÉAL, July 3, 2025 – In June, both Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) released...
-
CHS survey of people with hemophilia A and their caregivers
In June and July 2024, the Canadian Hemophilia Society conducted an online survey regarding the lived experience of people with hemophilia A and their caregivers....